HYPR vs PRCT vs NVCR vs INVA vs AEYE

For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.

2% revenue growth year-over-year, versus 5. 2% for Hyperfine, Inc. (HYPR). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Hyperfine, Inc. (HYPR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus HYPR's -83. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Hyperfine, Inc. 's 2. 63β — meaning HYPR is approximately 1984% more volatile than INVA relative to the S&P 500. On balance sheet safety, PROCEPT BioRobotics Corporation (PRCT) carries a lower debt/equity ratio of 14% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.

2% versus 5. 2% for Hyperfine, Inc. (HYPR). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 1. 7% for PROCEPT BioRobotics Corporation. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -262. 3% for Hyperfine, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -273. 4% for HYPR. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Hyperfine, Inc. (HYPR) carries a higher beta of 2. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, HYPR: -83. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HYPR (Healthcare) and PRCT (Healthcare) and NVCR (Healthcare) and INVA (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HYPR is a small-cap quality compounder stock; PRCT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; AEYE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.